Platelet P2Y12 receptor inhibition by thienopyridines: status and future

Thienopyridines have a well-established role in the treatment of coronary artery disease, especially in the setting of acute coronary syndromes and percutaneous coronary interventions. Ticlopidine, the first FDA-approved thienopyridine, was shown to be effective in reducing coronary events in high r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Expert opinion on investigational drugs 2009-09, Vol.18 (9), p.1317-1332
Hauptverfasser:	Porto, Italo, Giubilato, Simona, De Maria, Giovanni Luigi, Biasucci, Luigi Marzio, Crea, Filippo
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals antiplatelet drugs bleeding Blood Platelets - drug effects Blood Platelets - metabolism Clinical Trials as Topic Coronary Artery Disease - blood Coronary Artery Disease - drug therapy Drug Discovery - trends Humans Molecular Structure P2Y12 receptor Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - chemistry Platelet Aggregation Inhibitors - pharmacology Platelet Aggregation Inhibitors - therapeutic use Protein Binding Purinergic P2 Receptor Antagonists Pyridines - administration & dosage Pyridines - adverse effects Pyridines - chemistry Pyridines - pharmacology Pyridines - therapeutic use Receptors, Purinergic P2Y12 thrombosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!